2-Bromo-LSD

Last updated
2-Bromo-LSD
2-bromo-LSD structure.svg
Clinical data
Other names2-Bromolysergic acid diethylamide; 2-Bromo-LSD; 2-Br-LSD; BOL-148; BOL148; Bromolysergide; BETR-001; TD-0148A; NYPRG-101
Legal status
Legal status
  • Not scheduled (United States, Canada, Germany, EU precursors) [1] [2]
Identifiers
  • (6aR,9R)-5-bromo-N,N-diethyl-7-methyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
Formula C20H24BrN3O
Molar mass 402.336 g·mol−1
3D model (JSmol)
  • CCN(CC)C(=O)[C@H]1CN([C@@H]2CC3=C(NC4=CC=CC(=C34)C2=C1)Br)C
  • InChI=1S/C20H24BrN3O/c1-4-24(5-2)20(25)12-9-14-13-7-6-8-16-18(13)15(19(21)22-16)10-17(14)23(3)11-12/h6-9,12,17,22H,4-5,10-11H2,1-3H3/t12-,17-/m1/s1 Yes check.svgY
  • Key:VKRAXSZEDRWLAG-SJKOYZFVSA-N Yes check.svgY
 X mark.svgNYes check.svgY  (what is this?)    (verify)

2-Bromo-LSD, also known as BOL-148 or as bromolysergide, is a derivative of lysergic acid invented by Albert Hofmann, as part of the original research from which the closely related compound LSD was also derived. [3] [4] It is a non-hallucinogenic serotonin 5-HT2A receptor partial agonist, as well as acting at other targets, with psychoplastogenic and antidepressant-like effects in animals. [3]

Contents

Pharmacology

2-Bromo-LSD was found to be inactive as a psychedelic and so was comparatively little researched for many years, although its similar behaviour in the body made it useful for radiolabelling studies. It was found to bind to many of the same receptors as LSD, but acting as a neutral antagonist rather than an agonist. [5] [6] 2-Bromo-LSD reportedly attenuates the effects of LSD in humans. [7] [8]

In 2023, 2-bromo-LSD was characterised as a non-hallucinogenic serotonin 5-HT2A receptor biased partial agonist and as a serotonin 5-HT2B receptor antagonist. [3] [9] It shows weaker partial agonism of the serotonin 5-HT2A receptor than LSD (Emax = 60% vs. 92%, respectively). [3] [9] Unlike LSD, 2-bromo-LSD fails to produce the head-twitch response, a behavioural proxy of psychedelic effects, in animals. [3] [9] In addition, 2-bromo-LSD blocked the head-twitch response of the psychedelic DOI. [3] [9] 2-Bromo-LSD shows weak recruitment of β-arrestin2 and has reduced potential to induce tolerance in the form of serotonin 5-HT2A receptor downregulation. [3] [9] Similarly to LSD, the drug was also found to interact with numerous other serotonin receptors and targets. [3] However, 2-bromo-LSD reportedly shows less off-target activity compared to LSD. [3] [9]

In animals, 2-bromo-LSD shows psychoplastogenic (i.e., neuroplasticity-enhancing) effects and antidepressant-like effects. [3] [10]

Clinical development

The generally similar behaviour of 2-bromo-LSD to LSD in some respects has shown to be very useful in potential the treatment of cluster headaches. [11] These debilitating attacks have been known for some time to be amenable to treatment with certain hallucinogenic drugs such as LSD and psilocybin, but because of the illegal status of these drugs and the kind of mental changes they induce, research into their medical use has been slow and therapeutic application limited to very specific circumstances under strict supervision. It had been thought that this specific therapeutic action against cluster headaches was limited to hallucinogenic drugs of this type, and would always present a major barrier to their clinical use. However, a serendipitous discovery found that 2-bromo-LSD can also produce this therapeutic effect, despite lacking the other effects of LSD. This has led to a resurgence of interest and research into 2-bromo-LSD and its possible medical uses. Some isolated incidents of hallucinogenic responses with 2-bromo-LSD have been reported, but as with other non-hallucinogenic LSD analogs such as lisuride, this appears to be a rare side effect occurring only in individuals with an as yet unexplained susceptibility to this reaction.

2-Bromo-LSD, under the developmental code name BETR-001 (previously TD-0148A), is under development by BetterLife Pharma for the treatment of cluster headaches and other indications. [12] [13]

See also

References

  1. ↑ "BOL-148 hydrochloride". THC Pharm GmbH. Archived from the original on 2012-12-17. Retrieved 2019-04-23.
  2. ↑ "BetterLife Confirms Non-Controlled Status of 2-bromo-LSD with Health Canada - Psilocybin Alpha". Psychedelic Alpha. 19 January 2021.
  3. 1 2 3 4 5 6 7 8 9 10 Lewis V, Bonniwell EM, Lanham JK, Ghaffari A, Sheshbaradaran H, Cao AB, Calkins MM, Bautista-Carro MA, Arsenault E, Telfer A, Taghavi-Abkuh FF, Malcolm NJ, El Sayegh F, Abizaid A, Schmid Y, Morton K, Halberstadt AL, Aguilar-Valles A, McCorvy JD (March 2023). "A non-hallucinogenic LSD analog with therapeutic potential for mood disorders". Cell Rep. 42 (3): 112203. doi:10.1016/j.celrep.2023.112203. PMC   10112881 . PMID   36884348.
  4. ↑ Troxler F, Hofmann A (1957). "Substitutionen am Ringsystem der Lysergsäure. III. Halogenierung. 45. Mitteilung über Mutterkornalkaloide". Helvetica Chimica Acta. 40 (7): 2160–2170. doi:10.1002/hlca.19570400716.
  5. ↑ Ginzel KH, Mayer-Gross W (July 1956). "Prevention of psychological effects of d-lysergic acid diethylamide (LSD 25) by its 2-brom derivative (BOL 148)". Nature. 178 (4526): 210. Bibcode:1956Natur.178..210G. doi: 10.1038/178210a0 . PMID   13348662. S2CID   4169373.
  6. ↑ Isbell H, Miner EJ, Logan CR (November 1959). "Cross tolerance between D-2-brom-lysergic acid diethylamide (BOL-148) and the D-diethylamide of lysergic acid (LSD-25)". Psychopharmacologia. 1 (2): 109–116. doi:10.1007/bf00409110. PMID   14405871. S2CID   1915318.
  7. ↑ Mehta MA, Tricklebank MD (2019). "Serotonin and the psychedelics". The Serotonin System. pp. 193–202. doi:10.1016/B978-0-12-813323-1.00011-6. ISBN   9780128133231. S2CID   196510587.
  8. ↑ Tfelt-Hansen P (April 2011). "Is BOL-148 hallucinogenic?". Cephalalgia. 31 (5): 634, author reply 635-634, author reply 636. doi:10.1177/0333102410392069. PMID   21163816. S2CID   12412491.
  9. 1 2 3 4 5 6 Halberstadt A, Schmid Y, Bonniwell E, Lanham J, Ghaffari A, Cao A, Sheshbaradaran H, McCorvy J (December 2022). "ACNP 61st Annual Meeting: Poster Abstracts P271-P540: P349. Investigation of the Pharmacological Properties of 2-Br-LSD, a Non-Hallucinogenic LSD Analog". Neuropsychopharmacology. 47 (Suppl 1): 220–370 (264–265). doi:10.1038/s41386-022-01485-0. PMC   9714399 . PMID   36456694.
  10. ↑ Aguilar Valles A, Lewis V, Telfer A, Arsenault E, Taghavi-Abkuh FF, El Sayegh F, Abizaid A (December 2022). "ACNP 61st Annual Meeting: Poster Abstracts P271-P540: P358. A Non-Hallucinogenic LSD Analog With Therapeutic Potential for Mood Disorders". Neuropsychopharmacology. 47 (Suppl 1): 220–370 (269–270). doi:10.1038/s41386-022-01485-0. PMC   9714399 . PMID   36456694.
  11. ↑ Karst M, Halpern JH, Bernateck M, Passie T (September 2010). "The non-hallucinogen 2-bromo-lysergic acid diethylamide as preventative treatment for cluster headache: an open, non-randomized case series". Cephalalgia. 30 (9): 1140–1144. doi:10.1177/0333102410363490. PMID   20713566. S2CID   33199115.
  12. ↑ "BETR 001". AdisInsight. 29 August 2024. Retrieved 24 October 2024.
  13. ↑ "Delving into the Latest Updates on Bromolysergide with Synapse". Synapse. 14 October 2024. Retrieved 24 October 2024.

Further reading

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.